BioCentury | Dec 23, 2002
Clinical News

Porphozym: Phase I/IIa

...in 20 healthy volunteers and 20 patients, Porphozym reduced PBG to non-detectable levels in plasma. HemeBiotech A/S...
BioCentury | Oct 7, 2002
Clinical News

Acute intermittent porphyria therapeutic regulatory update

...The FDA granted Orphan Drug designation to HemeBiotech for an undisclosed compound that is in Phase...
...Phase I/II testing to treat acute intermittent porphyria, a hereditary disease related to porphyrin metabolism. HemeBiotech A/S...
BioCentury | Jan 22, 2001
Company News

HemeBiotech, Icogen deal

...agreement, Icogen will develop a mammalian cell-based system to produce a therapeutic protein for HemeBiotech. HemeBiotech A/S...
Items per page:
1 - 3 of 3
BioCentury | Dec 23, 2002
Clinical News

Porphozym: Phase I/IIa

...in 20 healthy volunteers and 20 patients, Porphozym reduced PBG to non-detectable levels in plasma. HemeBiotech A/S...
BioCentury | Oct 7, 2002
Clinical News

Acute intermittent porphyria therapeutic regulatory update

...The FDA granted Orphan Drug designation to HemeBiotech for an undisclosed compound that is in Phase...
...Phase I/II testing to treat acute intermittent porphyria, a hereditary disease related to porphyrin metabolism. HemeBiotech A/S...
BioCentury | Jan 22, 2001
Company News

HemeBiotech, Icogen deal

...agreement, Icogen will develop a mammalian cell-based system to produce a therapeutic protein for HemeBiotech. HemeBiotech A/S...
Items per page:
1 - 3 of 3